Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Mar 23, 2022 3:05pm
94 Views
Post# 34538733

RE:RE:RE:A few reminders from the KOL event a while back

RE:RE:RE:A few reminders from the KOL event a while backSorry LouisW - this is the data for the half life of sortilin internalization.  The TH1902 half life is, I believe, from their plasma studies done in mice. Remember the chart measuring the amount of docetaxal and TH1902 in the blood stream over time.  I believe that's where they got that from.

Wino115 wrote: It's not from their mice studies. It's from a paper they reference done by another team in a lab who were trying to find out how long sortilin took to internalize what it "scavenged" from the surface area of the cell. So, in other words, sort1 will grab the PDC and bring it into the cell in a very short time frame (but don't hold me to that interpretation as I really don't know the full extent of this lab experiment). And since the PDC is all out the body after 2 hours, the whole treatment is internalized quite rapidly, unlike an ADC that hangs around for 6-10 hours, spreading around and getting some in the tumor and some not.  It's from the following slide on the KOL presentation, entitled "SORT1 Rapidly Internalizes Ligands (progranulin) Increasing Half-Life".

Here's from the paper and the reference is below.  You may recognize the chart at 6E as that's what THTX used in their KOL presentation.

"Over the ensuing 10 minutes, nearly all Progranulin is removed from the cell surface of Sortilin-expressing cells. By 18 min, no diffuse plasma membrane Progranulin signal is visible, and limited signal remaining near the cell surface is concentrated in mobile puncta consistent with endosomes. The half-life for Progranulin bound to Sortilin at the cell surface is 4 min (Fig. 6E)"

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990962/


LouisW wrote: YOu mentioned "half life of TH1902 is 1 hour. " Is this in mouse? I would say that 1 hr is too shout for patients.




<< Previous
Bullboard Posts
Next >>